In addition, DASH diet consumption significantly reduces AST in patients below 44 years old (WMD: −5.298 IU/L, 95% CI: −7.994, −2.601, p < 0.001), 8 weeks' duration of study (WMD: −3.439 IU/L, 95% CI: −5.357, −1.521, p < 0.001), baseline serum AST over 28 IU/L (WMD: −4.382 IU/L, 95% CI: −6.524, −2.239, p < 0.001), BMI below 30 kg/m2 (WMD: −5.666 IU/L, 95% CI: −8.721, −2.61, p < 0.001), and patients with NAFLD (WMD: −5.298 IU/L, 95% CI: −7.994, −2.601, p < 0.001). Here, GOT1 is linked to metabolic dysfunction-associated steatotic liver disease.